We searched PubMed for articles published in English or Spanish between January, 1990, and March, 2010, with the terms “unusual yeasts”, “emerging fungal infections”, “non-albicans Candida”, “C. guilliermondii”, “C. krusei”, “C. parapsilosis”, “C. tropicalis”, “C. pseudotropicalis”, “C. lusitaniae”, “C. dubliniensis”, “C. glabrata”, “C. pelliculosa”, “C. kefyr”, “C. rugosa”, “C. famata”, “C. inconspicua”, “C. norvegensis”, “C. kefyr”, “C. orthopsilosis”, “C. metapsilosis”, “C. nivariensis
ReviewEmerging opportunistic yeast infections
Introduction
Candida albicans is the predominant cause of invasive fungal infections from yeasts.1, 2 Nevertheless, the epidemiology of yeast infections is rapidly evolving and non-albicans Candida species and other rare yeasts have emerged as major opportunistic pathogens (panel). Horn and colleagues1 showed that prevalence of candidaemia caused by non-albicans Candida species was 54·4%. Other yeasts that are less common than candida have been associated with life-threatening infections in immunocompromised hosts.3, 4, 5, 6 Although the importance of these emerging opportunistic yeasts is recognised, little is known about present epidemiological traits of these pathogens. Indeed, these pathogens are frequently difficult to identify by phenotypic methods and show variable susceptibility profiles to antifungal drugs.7, 8 We address the epidemiological, diagnostic, and therapeutic aspects of emerging yeast infections.
Section snippets
Non-albicans Candida species
Although C albicans is the most common cause of invasive fungal infections in hospital settings, the growing number of new infections from non-albicans Candida species is increasingly recognised as a major source of infection. In most surveys and treatment studies in the USA, Candida glabrata is the second most common Candida species leading to invasive fungal infections. The ARTEMIS Global Antifungal Surveillance Program9 showed that C albicans was the most common (63–70%) candidal cause of
Multiple yeast infections
Patients at a high risk for fungal infection (eg, candida, aspergillus, and mucor) can have more than one occurrence concomitantly or successively. Use of antifungal agents selects for resistant pathogens, much the same as occurs in antibacterial resistance. Prolonged use of voriconazole for prophylaxis or treatment can result in breakthrough fungal infections such as mucormycosis.
Jensen and colleagues75 showed that mixed fungaemia occurred in 15 (3%) of 530 cases of fungaemia and C albicans
Role of host status
Host and pathogen interactions are crucial in pathogenesis of invasive fungal infections. Traditionally, severity and outcomes from fungal infections are attributed to the pathogen's capability to overcome host immune defence and inflict tissue damage. However, whether host immunity is impaired, uncontrolled, or hyper-reactive affects the severity and outcome of invasive mycosis.77, 78, 79
Phagocytic cells (neutrophils and mononuclear phagocytes) are the effector cells of the innate immunity.80
Diagnostic considerations
Diagnosis of emerging yeast infections depends largely on traditional microbiological culture and identification methods and histopathology. Yeast fungaemia, especially that caused by Candida species, can be detected with blood cultures, although supplementation of lipids is usually required for growth of Malassezia species.88 Growth of Candida species from blood or normally sterile sites nearly always represents true infection and should be treated as such. However, growth of Candida species
Controversies for treatment and prevention
Additional strategies to improve outcomes for patients with invasive fungal infections include use of immunomodulators and combination therapies. Adjunctive interferon γ might be indicated for refractory cryptococcosis.109 The role of interferon γ in invasive candidosis and other emerging yeast infections is undefined. Although combination therapy is well established for treatment of cryptococcal meningitis, its use in invasive candidosis is less clear. Combination therapy is recommended for
Conclusions
Non-albicans Candida species and other rare yeasts are emerging as key opportunistic pathogens. Early and specific diagnosis is crucial, and the decision to treat a patient with these unusual infections is often based on little clinical and microbiological information. Treatment decisions need careful consideration of the institutional epidemiological factors and the immune status of the population at risk.
Search strategy and selection criteria
References (110)
Shifting patterns in the epidemiology of nosocomial Candida infections
Chest
(2003)- et al.
Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management
Clin Microbiol Infect
(2009) - et al.
Candida tropicalis fungaemia in adult patients with haematological malignancies: clinical features and risk factors
J Hosp Infect
(2002) - et al.
Biogeography of the yeasts of ephemeral flowers and their insects
FEMS Yeast Res
(2001) - et al.
Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review
Int J Antimicrob Agents
(2010) - et al.
Infections due to emerging and uncommon medically important fungal pathogens
Clin Microbiol Infect
(2004) Echinocandin antifungal drugs
Lancet
(2003)- et al.
Rhodotorula infection. A systematic review of 128 cases from literature
Rev Iberoam Micol
(2008) - et al.
Moulds, yeasts and aerobic plate counts in ginseng supplements
Int J Food Microbiol
(2006) - et al.
Moulds and yeasts in fruit salads and fruit juices
Food Microbiol
(2006)
Infection and colonisation of neonates by Hansenula anomala
Lancet
Saccharomyces cerevisiae infections and antifungal susceptibility studies by colorimetric and broth macrodilution methods
Diagn Microbiol Infect Dis
Epidemiology and outcome of multiple-species candidemia at a tertiary care center between 2004 and 2007
Diagn Microbiol Infect Dis
Differentiation and function of Th17 T cells
Curr Opin Immunol
TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells
Immunity
Robust Th1 and Th17 immunity supports pulmonary clearance but cannot prevent systemic dissemination of highly virulent Cryptococcus neoformans H99
Am J Pathol
Immune reconstitution syndrome associated with opportunistic mycoses
Lancet Infect Dis
Non-culture-based diagnostics for opportunistic fungi
Infect Dis Clin North Am
Approach to the diagnosis of invasive aspergillosis and candidiasis
Clin Chest Med
Molecular mechanism of hemolymph clotting system in Limulus
Thromb Res
Plasma (1→3)-β-D-glucan measurement in diagnosis of invasive deep mycosis and fungal febrile episodes
Lancet
Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry
Clin Infect Dis
Epidemiology of Candida albicans infections and role of non-Candida-albicans yeasts
Curr Drug Targets
Rhodotorula glutinis fungemia in a liver–kidney transplant patient
Transpl Infect Dis
Trichosporonosis in a tertiary care cancer center: risk factors, changing spectrum and determinants of outcome
Scand J Infect Dis
Saccharomyces cerevisiae fungemia: an emerging infectious disease
Clin Infect Dis
Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature
J Clin Microbiol
Candida nivariensis, an emerging pathogenic fungus with multidrug resistance to antifungal agents
J Clin Microbiol
Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing
J Clin Microbiol
The increased role of non-albicans species in candidaemia: results from a 3-year surveillance study
Mycoses
Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers
J Clin Microbiol
Active surveillance for candidemia, Australia
Emerg Infect Dis
Candida parapsilosis, an emerging fungal pathogen
Clin Microbiol Rev
Is Candida kefyr an emerging pathogen in patients with oncohematological diseases?
Clin Infect Dis
Etiological factors of fungemia in the Hospital San Martin in La Plata
Rev Argent Microbiol
Candida rugosa: a distinctive emerging cause of candidaemia. A case report and review of the literature
Scand J Infect Dis
Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole
Bone Marrow Transplant
Results from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole determined by CLSI standardized disk diffusion
J Clin Microbiol
Candida kefyr as an emerging pathogen causing nosocomial bloodstream infections in neutropenic leukemia patients
Clin Infect Dis
Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III
J Clin Microbiol
Molecular identification of unusual pathogenic yeast isolates by large ribosomal subunit gene sequencing: 2 years of experience at the United Kingdom mycology reference laboratory
J Clin Microbiol
Candida biofilms: an update
Eukaryot Cell
Biofilms of non-Candida albicans Candida species: quantification, structure and matrix composition
Med Mycol
Candida guilliermondii, an opportunistic fungal pathogen with decreased susceptibility to fluconazole: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program
J Clin Microbiol
Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program
J Clin Microbiol
Candida lusitaniae infections in the era of fluconazole availability
Clin Infect Dis
Replacement of Candida albicans with C. dubliniensis in human immunodeficiency virus-infected patients with oropharyngeal candidiasis treated with fluconazole
J Clin Microbiol
In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance
J Clin Microbiol
Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis
Antimicrob Agents Chemother
Cited by (642)
Diagnostic accuracy of clinical and laboratory characteristics in suspected non-surgical nosocomial central nervous system infections
2024, Journal of Hospital InfectionIn vitro evaluation of biofilm formation by Candida parapsilosis and Enterobacter cloacae. Scanning electron microscopy and efficacy of antimicrobial combinations study
2023, Diagnostic Microbiology and Infectious DiseaseAdding complexity to soil food webs: Myxobacteria have broad predation spectra with bacteria, yeasts and filamentous fungi in vitro
2023, European Journal of Soil BiologyHealth risk posed by direct ingestion of yeasts from polluted river water
2023, Water Research